tirzepatide glp1 and gip is a first-in-class dual agonist targeting both GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple When it comes to the

Samar Khalek, FNP-BC Board-Certified Family Nurse Practitioner Samar is a board-certified family nurse practitioner who supports clients throughout their GLP-1-based weight-loss journey with thoughtful, patient-focused care

While it is too early to say that GLP-1s prevent dementia, early results point toward meaningful cognitive protection

Quote: " The litigation is growing

Key efficacy results: - Up to 12.2% weight loss from baseline (26.6 lbs) at the highest dose - Up to 10.9% placebo-adjusted weight loss - Statistically significant, dose-dependent weight loss across all dose cohorts - Weight loss was progressive from Week 1 through Week 13 with no plateau observed - Significant differences versus placebo were observed for all doses above 15 mg starting at Week 1 Why "no plateau" matters: Most GLP-1 drugs show a weight loss plateau at some point the body adapts and weight loss slows